THE INTERSECTION OF BRAIN SCIENCE & HUMAN POTENTIALPartner with us
neurofeedback.com
The newsletter
← Research & Evidence
MixedRandomized controlled trial

A safety and feasibility randomized placebo controlled trial exploring electroencephalographic effective connectivity neurofeedback treatment for fibromyalgia.

The treatment appeared feasible and acceptable in this small trial. Pain and function improved similarly in the active and placebo groups.

Anderson L, De Ridder D, Glue P, Mani R, van Sleeuwen C, Smith M, Adhia DB.
Scientific reports · Publication date: 2025-01-02
Added to site: 2026-09-09
DOI: 10.1038/s41598-024-83776-8

Publication date recorded by Europe PMC; online and issue dates may differ.

Modalities
Neurofeedback, sLORETA
Clinical focus
Fibromyalgia, Pain
Population
People with fibromyalgia
Sample
30 participants: 15 active, 15 placebo
Intervention / method
12 sessions of EEG effective-connectivity neurofeedback
Comparator
Placebo neurofeedback

Clinician summary

This feasibility trial reported 80.5% adherence and no adverse events. Comparable improvements between groups do not demonstrate treatment-specific pain relief.

How to interpret the findings

Designed primarily for feasibility and safety, with a small sample. Absence of reported adverse events does not establish safety in larger populations.

Equipment and disclosures

Equipment details were not verified from the reviewed abstract.

Funding and competing-interest disclosures were not verified from the reviewed abstract.

Related evidence

Compare findings from the same clinical area, including mixed results.

Abstract checked · Checked 2026-09-09

Summary prepared with AI assistance. Source verification does not imply an independent replication or a clinician's endorsement. Read our review method.